|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen PL, Taghian AG, Katz MS, Niemierko
A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris
JR: Breast cancer subtype approximated by estrogen receptor,
progesterone receptor, and HER-2 is associated with local and
distant recurrence after breast-conserving therapy. J Clin Oncol.
26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
André F and Zielinski CC: Optimal
strategies for the treatment of metastatic triple-negative breast
cancer with currently approved agents. Ann Oncol. 23 (Suppl
6):vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M and Barbacid M: Cell cycle,
Cdks and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Plaks V, Kong N and Werb Z: The cancer
stem cell niche: How essential is the niche in regulating stemness
of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pavlopoulou A, Oktay Y, Vougas K, Louka M,
Vorgias CE and Georgakilas AG: Determinants of resistance to
chemotherapy and ionizing radiation in breast cancer stem cells.
Cancer Lett. 380:485–493. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Evans T, Rosenthal ET, Youngblom J, Distel
D and Hunt T: Cyclin: A protein specified by maternal mRNA in sea
urchin eggs that is destroyed at each cleavage division. Cell.
33:389–396. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suryadinata R, Sadowski M and Sarcevic B:
Control of cell cycle progression by phosphorylation of
cyclin-dependent kinase (CDK) substrates. Biosci Rep. 30:243–255.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nurse P and Thuriaux P: Regulatory genes
controlling mitosis in the fission yeast Schizosaccharomyces pombe.
Genetics. 96:627–637. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song X, Kenston SSF, Zhao J, Yang D and Gu
Y: Roles of FoxM1 in cell regulation and breast cancer targeting
therapy. Med Oncol. 34:412017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lange C and Calegari F: Cdks and cyclins
link G1 length and differentiation of embryonic, neural and
hematopoietic stem cells. Cell Cycle. 9:1893–1900. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neganova I, Tilgner K, Buskin A,
Paraskevopoulou I, Atkinson SP, Peberdy D, Passos JF and Lako M:
CDK1 plays an important role in the maintenance of pluripotency and
genomic stability in human pluripotent stem cells. Cell Death Dis.
5:e15082014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Opyrchal M, Salisbury JL, Iankov I, Goetz
MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis
E and D'Assoro AB: Inhibition of Cdk2 kinase activity selectively
targets the CD44+/CD24−/low stem-like
subpopulation and restores chemosensitivity of SUM149PT
triple-negative breast cancer cells. Int J Oncol. 45:1193–1199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun LH, Ban T, Liu CD, Chen QX, Wang X,
Yan ML, Hu XL, Su XL, Bao YN, Sun LL, et al: Activation of Cdk5/p25
and tau phosphorylation following chronic brain hypoperfusion in
rats involves microRNA-195 down-regulation. J Neurochem.
134:1139–1151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Falco G and Giordano A: CDK9: From
basal transcription to cancer and AIDS. Cancer Biol Ther.
1:342–347. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hatch VL, Marin-Barba M, Moxon S, Ford CT,
Ward NJ, Tomlinson ML, Desanlis I, Hendry AE, Hontelez S, van
Kruijsbergen I, et al: The positive transcriptional elongation
factor (P-TEFb) is required for neural crest specification. Dev
Biol. 416:361–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cortés N, Guzmán-Martínez L, Andrade V,
González A and Maccioni RB: CDK5: A unique CDK and its multiple
roles in the nervous system. J Alzheimers Dis. 68:843–855. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 1:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turner NC, Slamon DJ, Ro J, Bondarenko I,
Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al:
Overall survival with palbociclib and fulvestrant in advanced
breast cancer. N Engl J Med. 379:1926–1936. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Im SA, Lu YS, Bardia A, Harbeck N,
Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, et
al: Overall survival with ribociclib plus endocrine therapy in
breast cancer. N Engl J Med. 381:307–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goetz MP, Toi M, Campone M, Sohn J,
Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, et
al: MONARCH 3: Abemaciclib as initial therapy for advanced breast
cancer. J Clin Oncol. 35:3638–3646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Portman N, Alexandrou S, Carson E, Wang S,
Lim E and Caldon CE: Overcoming CDK4/6 inhibitor resistance in
ER-positive breast cancer. Endocr Relat Cancer. 26:R15–R30. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen L, Yang G and Dong H: Everolimus
reverses palbociclib resistance in ER+ human breast cancer cells by
inhibiting phosphatidylinositol 3-kinase(PI3K)/Akt/mammalian target
of rapamycin (mTOR) pathway. Med Sci Monit. 25:77–86. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kettner NM, Vijayaraghavan S, Durak MG,
Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, et al:
Combined Inhibition of STAT3 and DNA repair in
palbociclib-resistant ER-positive breast cancer. Clin Cancer Res.
25:3996–4013. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chien AJ, Rahmaputri S, Dittrich HF,
Majure MC, Rugo HS, Melisko ME and Goga A: A phase Ib trial of the
cyclin-dependent kinase inhibitor dinaciclib (dina) in combination
with pembrolizumab (P) in patients with advanced triple-negative
breast cancer (TNBC). J Clin Oncol. 37 (Suppl 15):S10722019.
View Article : Google Scholar
|
|
31
|
Rajput S, Khera N, Guo Z, Hoog J, Li S and
Ma CX: Inhibition of cyclin dependent kinase 9 by dinaciclib
suppresses cyclin B1 expression and tumor growth in triple negative
breast cancer. Oncotarget. 7:56864–56875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang J, Sergio CM, Sutherland RL and
Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not
CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast
cancer cells. BMC Cancer. 14:322014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tay Y, Zhang J, Thomson AM, Lim B and
Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions
modulate embryonic stem cell differentiation. Nature.
455:1124–1128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu L, Michowski W, Inuzuka H, Shimizu K,
Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, et al: G1
cyclins link proliferation, pluripotency and differentiation of
embryonic stem cells. Nat Cell Biol. 19:177–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anders L, Ke N, Hydbring P, Choi YJ,
Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P and
Sicinski P: A systematic screen for CDK4/6 substrates links FOXM1
phosphorylation to senescence suppression in cancer cells. Cancer
Cell. 20:620–634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wierstra I: Cyclin D1/Cdk4 increases the
transcriptional activity of FOXM1c without phosphorylating FOXM1c.
Biochem Biophys Res Commun. 431:753–759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xue J, Zhou A, Tan C, Wu Y, Lee HT, Li W,
Xie K and Huang S: Forkhead box M1 is essential for nuclear
localization of glioma-associated oncogene homolog 1 in
glioblastoma multiforme cells by promoting importin-7 expression. J
Biol Chem. 290:18662–18670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang N, Wei P, Gong A, Chiu WT, Lee HT,
Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes
β-catenin nuclear localization and controls Wnt target-gene
expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elango R, Vishnubalaji R, Manikandan M,
Binhamdan SI, Siyal AA, Alshawakir YA, Alfayez M, Aldahmash A and
Alajez NM: Concurrent targeting of BMI1 and CDK4/6 abrogates tumor
growth in vitro and in vivo. Sci Rep. 9:136962019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ghia P, Scarfò L, Perez S, Pathiraja K,
Derosier M, Small K, McCrary Sisk C and Patton N: Efficacy and
safety of dinaciclib vs ofatumumab in patients with
relapsed/refractory chronic lymphocytic leukemia. Blood.
129:1876–1878. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gregory G, Walker P, Mahadevan D, Wang D,
Chang J, Hernandez-Ilizaliturri F, Klein A, Rybka W,
Wagner-Johnston N, Escobar C, et al: Antitumor activity of
pembrolizumab plus dinaciclib in patients with diffuse large b cell
lymphoma: The phase 1b keynote-155 study. Hematol Oncol.
37:328–329. 2019. View Article : Google Scholar
|
|
42
|
Ravindran Menon D, Luo Y, Arcaroli JJ, Liu
S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC,
et al: CDK1 interacts with Sox2 and promotes tumor initiation in
human melanoma. Cancer Res. 78:6561–6574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Huang Y, Cai J, Ke Q, Xiao J,
Huang W, Li H, Qiu Y, Wang Y, Zhang B, et al: A
nestin-cyclin-dependent kinase 5-dynamin-related protein 1 axis
regulates neural stem/progenitor cell stemness via a metabolic
shift. Stem Cells. 36:589–601. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xie Q, Wu Q, Kim L, Miller TE, Liau BB,
Mack SC, Yang K, Factor DC, Fang X, Huang Z, et al: RBPJ maintains
brain tumor-initiating cells through CDK9-mediated transcriptional
elongation. J Clin Invest. 126:2757–2772. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moretto-Zita M, Jin H, Shen Z, Zhao T,
Briggs SP and Xu Y: Phosphorylation stabilizes Nanog by promoting
its interaction with Pin1. Proc Natl Acad Sci USA. 107:13312–13317.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nishi M, Akutsu H, Masui S, Kondo A,
Nagashima Y, Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, et
al: A distinct role for Pin1 in the induction and maintenance of
pluripotency. J Biol Chem. 286:11593–11603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang N, Wang C, Wang Z, Zona S, Lin SX,
Wang X, Yan M, Zheng FM, Li SS, Xu B, et al: FOXM1 recruits nuclear
Aurora kinase A to participate in a positive feedback loop
essential for the self-renewal of breast cancer stem cells.
Oncogene. 36:3428–3440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ring A, Nguyen C, Smbatyan G, Tripathy D,
Yu M, Press M, Kahn M and Lang JE: CBP/β-catenin/FOXM1 is a novel
therapeutic target in triple negative breast cancer. Cancers
(Basel). 10:5252018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Besharat ZM, Abballe L, Cicconardi F,
Bhutkar A, Grassi L, Le Pera L, Moretti M, Chinappi M, D'Andrea D,
Mastronuzzi A, et al: Foxm1 controls a pro-stemness microRNA
network in neural stem cells. Sci Rep. 8:35232018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Teh MT, Wong ST, Neill GW, Ghali LR,
Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in
basal cell carcinomas. Cancer Res. 62:4773–4780. 2002.PubMed/NCBI
|
|
51
|
Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N
and Luo S: Aberrant activation of hedgehog signaling promotes cell
proliferation via the transcriptional activation of forkhead box M1
in colorectal cancer cells. J Exp Clin Cancer Res. 36:232017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kalathil D, John S and Nair AS: FOXM1 and
cancer: Faulty cellular signaling derails homeostasis. Front Oncol.
10:6268362021. View Article : Google Scholar : PubMed/NCBI
|
